Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

03.08.2023 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update. “Our goal is to continue to bring life-changing medicines to patients with rare disease. Use of LIVMARLI in Alagille ...

Related Keywords

Canada , ,Sofinnova Investments Inc ,European Commission ,Mirum Pharmaceuticals Stock ,Phepatology Communications ,Frazier Life Sciences ,Health Canada ,Drug Administration ,Mirum Pharmaceuticals Inc ,Exchange Commission ,Nasdaq ,Travere Therapeutics ,Cerebrotendinous Xanthomatosis ,Alagille Syndrome ,New Drug Application ,Prescription Drug User Fee Act ,Avidity Partners ,Sofinnova Investments ,Call Details ,Breakthrough Therapy ,Fat Soluble Vitamin ,Mirum Pharmaceuticals ,Private Securities Litigation Reform Act ,Consolidated Statement ,